FWP

September 2013

Filed Pursuant to Rule 433

Registration Statement No. 333-190464

September 9, 2013

This

presentation

contains

forward-looking

statements

under

the

meaning

the

Private

Securities

Litigation

Reform

Act

1995.

These

statements

give

our

current

expectations

forecasts

and

use

words

such

“anticipate,”

“estimate,”

"expect,"

“believe,”

and

other

words

similar

meaning.

Any

all

the

forward-looking

statements

this

presentation

may

turn

out

wrong.

They

can

affected

inaccurate

assumptions

might

make

known

unknown

risks

and

uncertainties

including

but

not

limited

to,

the

efficacy

our

product

candidates,

their

efficacy

acceptable

dosage

levels,

the

ability

raise

capital

when

needed

and

reasonable

terms,

projections

potential

commercial

sales

company

products,

the

results

and

progress

clinical

trials,

developing

the

necessary

manufacturing

processes

and

gaining

all

necessary

regulatory

approvals,

both

the

United

States

and

internationally.

Consequently,

forward-looking

statement

can

guaranteed

and

actual

results

may

differ

materially.

Additional

information

concerning

factors

that

could

cause

actual

results

materially

differ

from

those

the

forward-looking

statements

are

contained

our

most

recent

reports

the

Securities

and

Exchange

Commission

including

our

Form

10-Q,

8-K

and

10-K

reports.

However,

undertake

obligation

publicly

update

forward-looking

statements,

whether

result

new

information,

future

events

otherwise.

note

these

factors

for

investors

permitted

the

Private

Securities

Litigation

Reform

Act

1995.

The

information

this

document

has

been

prepared

solely

for

informational

purposes

and

does

not

constitute

offer

sell

the

solicitation

offer

purchase

any

securities

from

any

entities

described

herein.

Any

such

offer

will

made

solely

means

the

prospectus

contained

the

registration

statement

(the

"Registration

Statement")

filed

OXiGENE,

Inc.

(the

"Company")

with

the

Securities

and

Exchange

Commission

(the

"SEC").

The

information

contained

herein

may

not

used

connection

with

offer

solicitation

anyone

any

jurisdiction

which

such

offer

solicitation

not

permitted

law

which

the

person

making

the

offer

solicitation

not

qualified

any

person

whom

unlawful

much

such

offer or solicitation.

INVESTING

SPECULATIVE

AND

INVOLVES

RISK

LOSS.

YOU

SHOULD

REVIEW

CAREFULLY

THE

REGISTRATION

STATEMENT,

INCLUDING

THE

DESCRIPTION

THE

RISKS

AND

OTHER

TERMS

BEFORE

MAKING

DECISION

INVEST.

The

Company

has

filed

Registration

Statement

(including

prospectus)

with

the

SEC

for

the

offering

which

this

presentation

relates.

Before

you

invest,

you

should

read

the

prospectus

contained

the

Registration

Statement,

the

information

incorporated

reference

into

the

Registration

Statement,

and

other

documents

the

Company

has

filed

with

the

SEC

for

complete

information

about

the

Company

and

the

offering.

You

may

get

these

documents

for

free

visiting

EDGAR

the

SEC

website

http://www.sec.gov

Alternatively,

the

Company

the

placement

agent

participating

the

offering

will

arrange

send

you

the

prospectus contained in the Registration Statement if you request it by calling H.C. Wainwright & Co., LLC at (212) 356-0500.

Safe Harbor And Free Writing Prospectus Statement

OXiGENE, Inc. (OXGN) Corporate Snapshot

Development-stage biotechnology company

Lead

product

candidate:

ZYBRESTAT

A vascular disrupting agent (VDA) being developed

primarily as an adjunctive cancer therapy which

has shown utility and tolerability to date in

combination

with

Avastin

and other cancer drugs

for ovarian cancer and other solid tumors

Follow-on product: OXi4503

–

generation,

dual-mechanism

VDA

being

developed for acute myeloid leukemia (AML)

Robust intellectual property (IP) portfolio

consists of more than 120 patents worldwide

OXiGENE Leadership Team

After many years of research,

we believe ZYBRESTAT

may

become the first

commercialized VDA…

…

attracting the support of

numerous prestigious

foundations, non-profit

research institutions and “big

pharma”

companies.

Where is the Opportunity?

Significant Therapeutic and Commercial Potential

Potential to significantly improve outcomes in solid tumor indications

Example: Antisoma received $75M upfront and $915 M in potential

development-based milestones for ASA404 from Novartis

Challenging Development History Limits Competition

Apart from OXiGENE only 3 other companies are known to be currently

developing

VDAs,

none

which

have

progressed

the

submission

stage

OXiGENE

believes

has

determined

the

optimal

way

ZYBRESTAT

should be developed and brought to the market

ZYBRESTAT

May Become the First Commercialized VDA

Clinically

meaningful

activity

with

significant

safety

issues

date

Previously identified cardiovascular response was found to be easily

managed with no abrogation of the anti-tumor effects

OXiGENE’s

ZYBRESTAT

(fosbretabulin,

CA4P)

Established Safety Profile (>400 patients)

No cumulative toxicities or cytotoxic-like side-effects

Manageable, transient mild-to-moderate hypertension

Manageable, transient myelosuppression with chemotherapy

Demonstrated Vascular Disrupting Activity

Single agent activity with partial and complete responses in solid tumors

Positive

results

combination

with

Avastin

(bevacizumab)

Positive

results

combination

with

Paraplatin

Taxol

Robust Intellectual Property (IP)

Protected by both composition-of-matter and method-of-use patents

Exclusive, worldwide license to the combretastatins discovered and

isolated by researchers at Arizona State University (ASU)

Unique, Dual Mechanism of Action

Tubulin-mediated cell shape change of endothelial and leukemic cells

Metabolized by oxidative enzymes (e.g., tyrosinases and peroxidases)

into an orthoquinone species with direct cytotoxic effects on tumor cells

Compelling Preclinical and Early Clinical Data

Recommended dose, objective responses and significant blood flow

reductions shown in Ph 1/2 studies in refractory solid tumors

Demonstrated near-complete elimination of FLT-3 mutated human AML

(leukemic clone) in systemic xenograft in SCID mouse model

Robust Intellectual Property (IP)

Protected by both composition-of-matter and method-of-use patents

Exclusive, worldwide license to the combretastatins discovered and

isolated by researchers at Arizona State University (ASU)

OXiGENE’s OXi4503: A 2nd-Generation VDA

OXiGENE’s Late-Stage Development Pipeline

ZYBRESTAT

Combination Therapy

Preclinical

Phase 1

Phase 2

Phase 3

With Paraplatin

(carboplatin) / Taxol

(paclitaxel) in anaplastic thyroid cancer

(ATC)

With Avastin

(bevacizumab) in ovarian

cancer

With Votrient

(pazopanib) in ovarian

cancer

With Taxol

(paclitaxel) in ovarian cancer

ZYBRESTAT

Single-Agent Therapy

Preclinical

Phase 1

Phase 2

Phase 3

Carcinoid syndrome

OXi4503 Single-Agent Therapy

Preclinical

Phase 1

Phase 2

Phase 3

Refractory acute myelogenous leukemia

(AML)

Ph. 2/3 completed

Ph. 2 ongoing

Ph. 2 planned

Ph. 1 ongoing

Ph. 1b/2 planned

Pre-EU MAA

OXiGENE (OXGN) Investment Thesis

Compelling Valuation

Currently trading at a market cap of less than $10 million

Leveraging $200+ million previously invested primarily in VDA development

Cost-Efficient and Risk-Mitigated Development Strategy

Ongoing and planned Ph 2 trials supported by foundations, non-profit research

institutions and larger pharmaceutical companies

Significant Potential Value-Creating Events on the Horizon

Enrollment complete for ongoing Avastin

+/-

ZYBRESTAT

Ph 2 in ovarian

cancer; Preliminary results expected 1H14

Potential initiation of Taxol

+/-

ZYBRESTAT

and Votrient

+/-

ZYBRESTAT

Ph 2 trials in ovarian cancer, as well as a Ph 1a/2b trial in carcinoid syndrome

Completion of enrollment for OXi4503 Ph 1 trial in AML

Actively pursuing development and commercialization agreements with

established industry leaders

Vascular Disrupting

Agents (VDAs)

Denying Tumors Oxygen

and Vital Nutrients

About Vascular Disrupting Agents (VDAs)

Proven Mechanism of Action

VDAs cut off blood supply to tumors, effectively

‘starving' them of oxygen and nutrients

Reducing blood supply is a proven mechanism

used by commercialized anti-VEGF drugs such

as Avastin

(bevacizumab) to treat cancer

Targeted Impact

VDAs disrupt blood flow and vasculature only

within tumors, sparing normal cells and organs

Broad Therapeutic Utility

Potentially useful in a wide range of tumors

Potentially improve clinical outcomes when

used in combination with other types of anti-

cancer therapies

Tumor Blood Flow Before VDA

Tumor Blood Flow After VDA

Product

Developer

Partner

Status

In Active Development

ZYBRESTAT

OXiGENE

Unpartnered;

Licensed from

Arizona State

University (ASU)

and BMS

Currently in pre-MAA stage for ATC in EU

Completed Ph 2b/3a with Paraplatin

(carboplatin) / Taxol

(paclitaxel) in

anaplastic thyroid cancer (ATC)

Currently in Ph 2 with Avastin

(bevacimuzab) in ovarian cancer

Planned Ph 2 with Votrient

(pazopanib) in ovarian cancer

Planned Ph 2 with Taxol

(paclitaxel) in ovarian cancer

Planned Ph 1/2 trial in carcinoid syndrome (IP from AngioGene)

OXi4503

OXiGENE

Unpartnered;

ASU License

Currently in Phase 1 in acute myelogenous leukemia

BNC105

Bionomics

Unpartnered

Currently in Ph 2 in combination with chemotherapy in both renal

cell and

ovarian cancers

NPI-2358

(plinabulin)

Nereus

Unpartnered

Completed Ph 1 and Ph 2 clinical trials for solid tumors and NSCLC

(combination with docetaxel); no ongoing trials

Crolibulin

EpiCept

Immune Pharma

Ltd.

Currently in Phase 1/2 in combination with cisplatin in solid tumors with

focus on ATC

No Longer in Active Development

AVE8062

Ajinomoto

SanofiAventis

Active but limited IP

ASA404

Antisoma

Novartis

Failed in Ph 3

Denibulin

AngioGene

MediciNova

Cardiac toxicity in Ph 2

ZD6126

AstraZeneca

AngioGene

Cardiac toxicity in Ph 2

VDA Competitive Landscape

ZYBRESTAT

Program

in Ovarian Cancer

Why Ovarian Cancer?

Aggressive, stealthy cancer

~22,000 new cases in the U.S. annually,

~220,000 new cases worldwide

Over 60% of patients have distant spread

at diagnosis resulting in poor prognosis

Dire need for better therapies

Highly lethal cancer that is responsible

for the deaths of approximately 14,000

women in the U.S. each year

Rapid resistance to existing FDA-

approved treatments ultimately limits

their effectiveness

5-year survival rates of only 47%, largely

unchanged since the 1990s

•

Annual Incidence And Mortality Rates

of Female Cancers Worldwide

•

Ovarian Cancer Spread at Diagnosis

Risk-Mitigated, Cost Effective Development

Avastin

(bevacizumab) +/-

ZYBRESTAT

Co-Sponsored by Gynecologic Oncology Group (GOG),

National Cancer Institute (NCI), and Genentech / Roche

Ongoing Ph 2 trial (GOG186I) in ovarian cancer

First randomized combination study of Anti-VEGF + VDA compounds

2nd-

or 3rd-line therapy for platinum-resistant ovarian cancer

Primary endpoint: Median progression free survival (PFS)

Goal: Improvement in PFS from 50% (Avastin

) to 65% (Combination)

Enrollment complete at 107 patients at 80+ clinical sites; preliminary

results expected 1H14

Rationale: Positive Ph 1 and preclinical trial results

Disease stabilization in 9/14 (60%) treated patients who had failed

multiple prior therapies

Votrient

(pazopanib)

+/-

ZYBRESTAT

Potentially Sponsored by UK Non-Profit Cancer Research

Organization and Drug Manufacturers Involved

Planned Randomized, Placebo-controlled Ph 2 trial

Up to 120 patients with platinum-resistant ovarian cancer

Primary endpoint: Median progression free survival (PFS)

Initiation expected 1H14

Rationale: Positive Ph 1 and Preclinical Trial Results

Positive

results

with

Avastin

ZYBRESTAT

Anti-angiogenic

multi-kinase

inhibitors

ZYBRESTAT

significantly

reduced tumor growth rates in preclinical tumor models

OXiGENE’s Estimated Cost: < $1M

Weekly Taxol

(paclitaxel) +/-

ZYBRESTAT

OXiGENE’s Estimated Cost: ~$1M w/ or ~$8M w/o Co-Sponsor

ZYBRESTAT

Program

in Carcinoid Syndrome

Carcinoid Syndrome

Slow-Growing, Biologically

Active GI Tumors

Neuroendocrine tumors (NETs) that

overproduce biologically active

substances such as serotonin

Causes debilitating symptoms,

including episodic flushing, diarrhea,

wheezing, and potentially carcinoid

heart disease

Limited Therapeutic Options

Somatostatin

analogues

such

Sandostatin

(octreotide)

help

control symptoms, but the effect is often only temporary

Non-responders are limited to surgical resection and/or chemotherapy,

for which patients are often ineligible

Sandostatin

(octreotide) +/-

ZYBRESTAT

Planned Ph. 1b/2a Self-Controlled Study

20 Sandostatin

-refractory carcinoid syndrome patients with

increased biomarker (5-HIAA and/or chromogranin A) levels

Primary endpoints: Biomarker (5-HIAA and/or chromogranin A) levels

Secondary endpoints: Symptom control, QoL

Rationale: Positive Preclinical Results, Potentially Rapid

Development Pathway, Robust Intellectual Property

Positive preclinical data in prolactinoma and insulinoma models

Potentially rapid readout and development based on biomarkers

Exclusive, worldwide licensing agreement with Angiogene

Pharmaceuticals for the use of VDAs in the treatment of carcinoid

syndrome and other neuroendocrine tumors (NETs)

OXiGENE’s Estimated Cost: ~$3M

ZYBRESTAT

Program

in Anaplastic Thyroid

Cancer (ATC)

ZYBRESTAT

in Anaplastic Thyroid Cancer

Completed Randomized Ph. 2/3 (FACT) Trial Results

80 patients with biopsy-proven ATC at 40 clinical sites

Paraplatin

(carboplatin)

Taxol

(paclitaxel)

+/-

ZYBRESTAT

Primary endpoint: Median survival: 5.2 vs. 4.0 months (NS), HR 0.72

Secondary endpoints: 1-year survival 26 vs. 9%; OR rate 20 vs. 16%

Target 1H16 EMA marketing authorization in EU

Potential

for

approval

via

“Exceptional

Circumstances”

pathway

May not require additional clinical data

Anaplastic Thyroid Cancer (ATC)

Highly aggressive and lethal cancer with limited

treatment options

~2,000 total patients annually in the US and EU

Orphan drug status in both the US and EU

OXiGENE’s Estimated Cost: ~$5M remaining

Paraplatin

Taxol

ZYBRESTAT (N=55)

Paraplatin

Taxol

(N=25)

Median Survival

(95% CI)

5.2 months

(3.1, 9.0)

4.0 months

(2.8, 6.2)

One-year Survival

25.5%

8.7%

Hazard Ratio

(95%CI)

0.72 (0.43, 1.20)

28% Risk Reduction

•

Survival Time (Months)

Results from Ph 2/3 (FACT) Study in ATC

OXi4503 Program

in Acute Myelogenous

Leukemia (AML)

OXi4503 in Acute Myelogenous Leukemia

Ongoing Ph 1 Dose-Escalation Study

Co-sponsored by the University of Florida, the Leukemia and Lymphoma

Society

Up to 36 relapsed and refractory acute myelogenous leukemia (AML) or

myelodysplastic syndrome

patients

Primary endpoint: Recommended dose

Secondary endpoint: Hematologic responses

Rationale: Positive Preclinical Trial Results and Robust

Intellectual Property

Demonstrated near-complete elimination of FLT-3 mutated human AML

(leukemic clone) in systemic xenograft in SCID mouse model

Composition-of-matter and method-of-use patents for myeloid-lineage

leukemias

OXiGENE (OXGN)

Corporate Summary

Financial Overview

Cost-Efficient, “Virtual Company”

Infrastructure

Cash: $7.7M (2Q13), projected to last into 2Q14

Raised $6.1M in early 2013 via ATM and PIPE

Reduced expenses by more than 30% in 2012

Debt: $0M (2Q13)

Common Stock: 2.7M outstanding (6.8M fully diluted)

Prioritized Spending Needs

Avastin

combo (GOG0186I) in ovarian cancer (<$1M remaining)

Votrient

combo in ovarian cancer (<$1M in future spending)

Taxol

combo in ovarian cancer ($1-8M in future spending)

MAA

filing

for

Paraplatin

Taxol

combo

ATC

(~$5M,

some

which may be recovered via commercialization of registration lots)

Carcinoid syndrome Ph 1 program (~$3M)

Robust Intellectual Property Portfolio

ZYBRESTAT®

United States

Europe

Japan

Composition of Matter: fosbretabulin

tromethamine

September 2021

US 7659261, 7524832 &

7659262

September 2021

EPO 1320534

September 2021

JP 4149804

Method of modulating tumor growth

or metastasis by administration of fosbretabulin

and paclitaxel

December 2021

US 6,538,038

N/A

Method of treating NET including carcinoid

tumor symptoms by administering fosbretabulin

June 2033

PCT* pending

June 2033

PCT *pending

June 2033

PCT* pending

OXi4503

Composition of Matter: OXi4503 –

salt form

including potassium

October 2021

US 7,078,552

April 2021

EPO 1278758

February 2020

pending

Method of treating myeloid neoplasm by

administering OXi4503

November 2028

JP 5302328

•

*A Patent Cooperation Treaty (PCT) application establishes a filing date in all 148 contracting states.

OXiGENE is the owner or exclusive licensee

of more than 120 patents worldwide

2013

2H13: Ongoing

dialogue with EMA

regarding EU MAA for

ZYBRESTAT

in ATC

2H15: Initial data from

potential Ph 2 Taxol

and

Votrient

+/-

ZYBRESTAT

combo trials

2H15: Potential EMA MAA

submission for ZYBRESTAT

in ATC

2014

2015

2016

2017

Numerous Upcoming Catalysts

2017: Potential FDA

NDA submission for

Avastin

+/-

ZYBRESTAT

combo in

ovarian cancer

1H14: Preliminary data from

ongoing Ph 2 Avastin

+/-

ZYBRESTAT

combo trial (GOG-

186I)

1H14: Potential initiation of Ph

2 Taxol

+/-

ZYBRESTAT

combo trial

1H14: Potential initiation of Ph

2 Votrient

+/-

ZYBRESTAT

combo trial

2016 : Potential EU MAA approval for

ZYBRESTAT

in ATC

2016: Potential final data from Ph 2

Taxol

and Votrient

+/-

ZYBRESTAT

combo trials

2016: Potential final data from Ph 3

Avastin

+/-

ZYBRESTAT

combo

trials

OXiGENE (OXGN) Investment Thesis

Compelling Valuation

Currently trading at a market cap of less than $10 million

Leveraging $200+ million previously invested primarily in VDA development

Cost-Efficient and Risk-Mitigated Development Strategy

Ongoing and planned Ph 2 trials supported by foundations, non-profit research

institutions and larger pharmaceutical companies

Significant Potential Value-Creating Events on the Horizon

Enrollment complete for ongoing Avastin

+/-

ZYBRESTAT

Ph 2 in ovarian

cancer -

preliminary results expected 1H14

Potential initiation of Taxol

+/-

ZYBRESTAT

and Votrient

+/-

ZYBRESTAT

Ph 2 trials in ovarian cancer, as well as a Ph 1a/2b trial in carcinoid syndrome

Completion of enrollment for OXi4503 Ph 1 trial in AML

Actively pursuing development and commercialization agreements with

established industry leaders